Panel Clarifies Venue In Patent Disputes Over Proposed Generics

Mealey's (November 6, 2020, 9:12 AM EST) -- WASHINGTON, D.C. — In a Nov. 5 holding, the Federal Circuit U.S. Court of Appeals applied the U.S. Supreme Court’s standard for determining venue in a patent infringement action to generic drug disputes and found that infringement “occurs” only in districts “where actions related to the submission” of an abbreviated new drug application (ANDA) took place (Valeant Pharmaceuticals North America LLC, et al. v. Mylan Pharmaceuticals Inc., et al., No. 19-2402, Fed. Cir.)....